Curt I Civin

US Patent:

7767202, Aug 3, 2010

Filed:

Mar 18, 2002

Appl. No.:

10/471559

Inventors:

Drew M. Pardoll - Brookeville MD, US
Linzhao Cheng - Columbia MD, US
Yan Cui - New Orleans LA, US
Curt I Civin - Towson MD, US
Katherine Whartenby - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 48/00

US Classification:

424 9321, 424 932, 435375

Abstract:

The invention provides methods and compositions for the modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules. The invention includes bi-cistronic lentiviral expression vectors adapted for antigen expression in antigen presenting cells for use in DNA vaccines directed against pathogens and tumor antigens as well as for the treatment of autoimmune disease and for the establishment of antigen tolerance.

US Patent:

7799528, Sep 21, 2010

Filed:

Aug 9, 2005

Appl. No.:

11/199665

Inventors:

Curt I. Civin - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The invention is based at least in part on the discovery of novel group of genes and/or their encoded gene products that are differentially represented in two substantially enriched CD34/CD38/Lin and CD34/[CD38/Lin] hematopoietic cell populations isolated from normal human bone marrow, cord blood, and peripheral blood stem cell preparations.

US Patent:

20040131599, Jul 8, 2004

Filed:

Feb 25, 2004

Appl. No.:

10/471881

Inventors:

Curt Civin - Towson MD, US
Daniel Drachman - Stevenson MD, US
Katherine Whartenby - Baltimore MD, US
Drew Pardoll - Brookville MD, US

International Classification:

A61K048/00
C12N005/08

US Classification:

424/093210, 435/372000

Abstract:

The invention provides methods and compositions utilizing FasL armed donor graft cells to reduce or eliminate host allogeneic or xenogeneic graft rejection, and FasL armed host cells to reduce or eliminate graft versus host disease.

US Patent:

20100184032, Jul 22, 2010

Filed:

Jun 4, 2009

Appl. No.:

12/478586

Inventors:

Robert Georgantas - Towson MD, US
Curt I. Civin - Towson MD, US
George Adrian Calin - Columbus OH, US
Carlo Maria Croce - Columbus OH, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD

International Classification:

C12N 5/0789
C12Q 1/68

US Classification:

435 6, 435377, 435325

Abstract:

Provided herein are methods and compositions for modulating the differentiation of incompletely differentiated cells, such as stem-progenitor cells, e.g., hematopoietic stem-progenitor cells. A method may comprise contacting a cell with an agononist or an antagonist of a miRNA comprising a nucleotide sequence from SEQ ID NO: 1-34.

US Patent:

51378094, Aug 11, 1992

Filed:

Jul 19, 1990

Appl. No.:

7/572303

Inventors:

Michael R. Loken - Los Altos CA
Curt I. Civin - Baltimore MD
Virendra O. Shah - Cupertino CA

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

G01N 33533

US Classification:

435 721

Abstract:

A method and kit for identification of the lineages and stages of hematopoietic cells in a sample wherein the cells are treated with labeled monoclonal antibodies selected to distinguish between each lineage and maturational stages within each lineage.

US Patent:

47146800, Dec 22, 1987

Filed:

Feb 6, 1984

Appl. No.:

6/670740

Inventors:

Curt I. Civin - Baltimore MD

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12N 502
G01N 33577

US Classification:

43524025

Abstract:

Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.

US Patent:

59167920, Jun 29, 1999

Filed:

Jan 6, 1998

Appl. No.:

9/003289

Inventors:

Curt I. Civin - Baltimore MD
Donald Small - Baltimore MD
Meredith G. Safford - Baltimore MD

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C07K 14435
C12N 912

US Classification:

435194

Abstract:

A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.

US Patent:

51301440, Jul 14, 1992

Filed:

Mar 22, 1991

Appl. No.:

7/673721

Inventors:

Curt I. Civin - Baltimore MD

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 3528
C12N 508

US Classification:

424577

Abstract:

Monoclonal antibodies that recognize a stage-specifc antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marror transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.